|
|
Trupti Joshi, Ph.D.
November 11, 2011
202.857.6410
trupti.joshi@arentfox.com
Trupti Joshi is a patent agent in the Intellectual property group. Trupti’s work is focused on preparing and prosecuting patent applications and counseling clients in various areas including biotechnology, pharmaceutical, chemistry, and life sciences. Trupti is also involved in preparing and prosecuting design patent applications.
Previous WorkPrior to Arent Fox, Trupti was a patent technical specialist at a Washington, DC law firm where she participated in patent prosecution of biotechnology patents.
Trupti also worked as a post-doctorate fellow at the Johns Hopkins University where she focused her research on characterizing the role of dendritic cells and T cells in parasitic diseases.
Publications, Presentations and RecognitionsTrupti has published several peer-reviewed articles. A list of her selected publications includes:
- "IRF5 deficiency severely impairs the development of T helper 1 responses following Leishmania donovani infection," Paun, A., Joshi, T., Pitha, P.M., and Stäger,S. 2011, PLoS Pathogens, 7 (1): 1001246
- "B7-H1 blockade increases survival of dysfunctional CD8+ T-cells and confers protection against Leishmania donovani infections," Joshi, T., Rodriguez, S., Perovic, V., Cockburn, I., and Stäger,S. 2009, PLoS Pathogens,5(5):e1000431
- "IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro," Gowda A, Roda JM, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC, Blood, May 1, 2008, 111(9):4723-30
- "The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines," Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd, Clinical Cancer Research, November 1, 2007, 13(21):6419-28
- "Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical," Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC, Blood, October 1, 2007, 110(7):2569-77
- “Fcgamma receptor signaling in phagocytes,” Joshi T, Butchar JP,Tridandapani S, International Journal of Hematology, October 2006, 84(3):210-16
- FcgR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways," Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S, Blood, July 15, 2006, 108(2):718-25
- "Molecular analysis of expression and function of hFcgRIIbl and b2 isoforms in myeloid cells," Joshi T, Ganesan LP, Cao X, Tridandapani S, Molecular Immunology, March 2006, 43(7):839-50
Life Beyond the LawTrupti enjoys exercising and traveling. She is fluent in Hindi and Marathi.
EducationOhio State University , PhD
|
|